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Purpose: To evaluate the diagnostic accuracy of routinely used tests of visual function and retinal
morphology compared with fundus fluorescein angiography (FFA) to detect onset of active macular neo-
vascularization in unaffected fellow eyes of patients with unilateral neovascular age-related macular degeneration
(nAMD).
Design: Prospective diagnostic accuracy cohort study conducted in 24 eye clinics in the United Kingdom
over 3 years.
Participants: Older adults (>50 years) with recently diagnosed unilateral nAMD with a fellow (study) eye free
of nAMD.
Methods: Self-reported vision, Amsler, clinic-measured visual acuity (VA), fundus assessment, and spectral
domain OCT. The reference standard is FFA.
Main Outcome Measures: Sensitivity and specificity of the 5 index tests.
Results: Of 552 participants monitored for up to 3 years, 145 (26.3%) developed active nAMD in the study
eye, of whom 120 had an FFA at detection and constituted the primary analysis cohort. Index test positives at
nAMD detection in those confirmed by FFA were self-reported vision much worse (5), distortion on Amsler (33),
10-letter decrease in acuity from baseline (36), fundus examination (64), and OCT (110). Percentage index test
sensitivities were: self-reported vision 4.2 (95% confidence interval [CI], 1.6e9.8); Amsler 33.7 (95% CI,
25.1e43.5); VA 30.0 (95% CI, 22.5e38.7); fundus examination 53.8 (95% CI, 44.8e62.5); and OCT 91.7 (95% CI,
85.2e95.6). All 5 index test specificities were high at 97.0 (95% CI, 94.6e98.5), 81.4 (95% CI, 76.4e85.5), 66.3
(95% CI, 61.0e71.1), 97.6 (95% CI, 95.3e98.9), and 87.8 (95% CI, 83.8e90.9), respectively. The combination of
OCT with one other index test that was a secondary outcome measure increased sensitivity marginally and
decreased specificity for all combinations except fundus examination.
Conclusions: Tests of self-reported change in vision, unmasking of new distortion, measurements of acuity,
and fundus checks to diagnose active nAMD performed poorly in contrast to OCT. Our findings support a change
to guidelines in clinical practice to monitor for onset of nAMD. Ophthalmology 2021;128:1736-1747 Crown
Copyright ª 2021 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Supplemental material available at www.aaojournal.org.Neovascular age-related macular degeneration (nAMD) is an
important cause of severe vision loss in older people because
it commonly affects both eyes and has an enormous impact on1736 Crown Copyright ª 2021 Published by Elsevier Inc. on behalf of the Ame
Academy of Ophthalmology. This is an open access article under the CC
(http://creativecommons.org/licenses/by/4.0/).quality of life.1,2 Over the past decade, treatment with
intravitreal anti-vascular endothelial growth factor (VEGF)
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obtained from electronic medical records of patients with
bilateral nAMD treated with anti-VEGF shows that second
eyes with generally good visual acuity (VA) at diagnosis
maintain better function over 3 years compared with first eyes
that commenced treatment with on average lower levels of
VA.4 Traditionally, detection of nAMD at onset is made by
fundus fluorescein angiography (FFA), which is the
confirmatory diagnostic test according to the Age-Related
Macular Degeneration Practice Patterns of the American
Academy of Ophthalmology.5 Fundus fluorescein
angiography is an invasive procedure requiring the
intravenous injection of fluorescein dye and capture of a
sequence of retinal images through a dilated pupil for up to
10 minutes using a specialized camera. This test requires
compliant patients, skilled photographers, and medical
support for intravenous cannulation and administration of
the dye with monitoring for local and systemic reactions
including anaphylaxis. The acquired retinal images require
review by an experienced retina specialist for the presence
of signs of nAMD.
Once nAMD has developed in the first eye, approximately
one-quarter of persons will develop neovascularization in
their fellow eye within 3 years.6 Several strategies are used to
detect the onset of nAMD promptly in the unaffected fellow
eyes, but these have not been compared to inform what
would now be best practice. Clinicians advise their patients
to self-monitor the unaffected fellow eye between sched-
uled clinic visits for symptoms of onset of disease. Patients
may be provided with an Amsler chart, which is a high-
contrast grid of black lines printed on a white background
and is viewed at reading distance monocularly. Visual change
such as perceived distortion of the grid can signify the onset of
nAMD.5,7When patients with nAMD in 1 eye attend hospital
eye services for treatment, VA, fundus examination, and
spectral-domain OCT are commonly used to monitor the
fellow eye.8 The instrumentation used for OCT is a
noncontact, user-friendly noninvasive technology that is
used to rapidly acquire depth-resolved images of the posterior
fundus allowing the signs of onset of nAMD to be detected.8,9
Although retrospective case series of symptomatic patients
imaged with both FFA and OCT show high levels of
diagnostic agreement,10,11 our literature searches revealed
no robust prospective data and OCT has become adopted
into routine clinical practice for establishing a diagnosis of
nAMD. One study has suggested a moderate false-positive
rate with OCT, increasing the risk of patients being mistak-
enly diagnosed with nAMD and thus inappropriately treated
with costly anti-VEGF therapies.10 A newer addition to the
noninvasive imaging technologies that can provide
information on the ocular circulation is OCT angiography.
OCT angiography of the fundus reveals the
microcirculation of the retina in exquisite detail that can
distinguish vascular components down to the capillaries and
resolve the different layers of blood vessels in the retina and
choroid. At present, its interpretation, application, and value
in determining onset of nAMD remain under investigation.12
Because the benefit in terms of maintained good vision is
considerably greater if treatment is commenced promptly in
confirmed nAMD4 and there is a lack of robust evidence ofthe diagnostic accuracy of commonly used monitoring tests,
we conducted a prospective diagnostic accuracy study to
evaluate the best test or combination of monitoring tests
that can be performed to robustly and efficiently detect
nAMD in second eyes of those with nAMD in the first eye.
Methods
The Early Detection of Neovascular Age-Related Macular
Degeneration (EDNA) study was a 3-year multicenter, prospective,
cohort, comparative diagnostic accuracy study conducted in a
monitoring setting in 24 ophthalmology departments within UK
NHS hospitals. The Office for Research Ethics Committees in
Northern Ireland reviewed and approved this study (14/NI/1120),
and the study was prospectively registered on ISRCTN
(48855678). Informed consent was obtained for all patients, and
the study followed the Declaration of Helsinki.
Eligibility criteria were persons aged 50 years or more with
newly diagnosed nAMD in 1 eye and an unaffected fellow eye
confirmed to be free of nAMD by FFA and with a best-corrected
VA of  68 ETDRS letters (Snellen equivalent 20/40 or better)
with no confounding retinal pathology. The unaffected fellow eye
was the study eye. Exclusion criteria were inability to attend for
regular treatment of the first affected eye, refusal of informed
consent, and lack of a diagnostic FFA or one that was performed
more than 6 weeks before enrollment. The selection criteria were
specifically chosen because patients with nAMD attend to receive
repeated injections of anti-VEGFs, so enabling regular monitoring
of the fellow eyes using a panel of index tests.
Identification of Participants
Consecutive eligible patients were identified by the clinician or
research nurse in the ophthalmology clinics. Potentially eligible
patients were invited to attend a baseline study visit where eligi-
bility was assessed in full and written informed consent was
obtained.
Index Tests
We selected 5 tests composed of a mixture of function and
morphology that are commonly used and recommended for
assessment and monitoring of patients with any stage of age-related
macular degeneration (AMD) early or late. These were self-
reported vision, the Amsler test, VA, fundus examination, and
OCT performed at each visit.
Self-Reported Vision
Participants were asked a standardized question to ascertain if there
had been any subjective worsening of vision in the EDNA study
eye compared with the previous clinic visit. These data were
collected using a questionnaire.
Amsler
Participants self-recorded the presence of distortion if any in the
EDNA study eye on Amsler charts immediately before or during
clinic visits according to instructions that had been provided before
enrollment.
Visual Acuity
All sites recorded theVA from both eyes of participants at every visit.
Acuity was measured on EDTRS charts as the number of letters read.
Site staff specified whether the acuity assessment was undertaken1737
Ophthalmology Volume 128, Number 12, December 2021unaided, with habitual refraction, pinhole, or best corrected with the
same method used for baseline and all follow-up visits.
OCT
OCT images were captured at routine clinic visits using local
protocols. Enhanced depth imaging was an optional extra.
Fundus Examination/Photography
This was assessed by slit-lamp clinical examination or from fundus
photography that included fields 1 and 2 comprising the central
macula. If a widefield camera was used, a single image was
sufficient.
Participant Follow-up
A fluorescein angiogram conducted at referral confirmed the
absence of nAMD in the EDNA study eye. At enrollment, par-
ticipants were instructed on self-monitoring of vision and testing
of the study eye with the Amsler chart. These 2 tests were self-
administered before or at each routine clinic visit. All other in-
dex tests were conducted during the visit. If the Amsler at the
baseline visit was abnormal, participants were eligible to take part
in EDNA. However, no further Amsler tests were collected
during follow-up visits. The protocol required the patient to un-
dergo an FFA in the event that any of the index tests were pos-
itive (a trigger) for nAMD. In the event of a positive FFA, the
participant exited the study. All participants with negative FFA
were followed up for a minimum of 30 months or up to 3 years.
In the absence of a trigger arising from a positive index test, 2
additional planned study visits were undertaken at month 18 and
on completion of the study (study exit). At these visits, protocol-
based study procedures for the measurement of all index tests,
self-reported vision, Amsler, VA retinal imaging (color photog-
raphy, SD-OCT), and fluorescein angiography were performed
(Fig S1, available at www.aaojournal.org).
Definitions of Positive Index Tests1731. Self-reported vision: A positive test was defined as a
worsening reported by the participant for subjective
assessment of vision in the EDNA study eye. This
was assessed using the following question: “How is
your vision in the (unaffected) eye compared to the
last visit?” with the following 4 possible answers:
“about the same or better,” “a bit worse,” “worse,”
or “much worse.” “Much worse” triggered an FFA.
2. The Amsler test: A positive Amsler test was defined
as the reporting by the patient of the appearance of
distortion in the grid or disappearance of regions of
the grid pattern (scotoma) on the Amsler chart.
Because of the known high rate of false-positives,
this test was only performed during follow-up after
confirming the existence of a distortion free Amsler
test completed at baseline.
3. Visual acuity tested on ETDRS vision charts: A
positive test was defined as a reduction of 10 or
more letters in VA from the baseline measurement.
4. Fundus clinical evaluation: Biomicroscopic exami-
nation of the eye or interpretation of the color
fundus images was made by an appropriately qual-
ified member of the study team. A positive test was8
the presence of clinical signs of active nAMD on
slit-lamp biomicroscopy that included elevation of
the macular retina or the presence of edema, hem-
orrhage, lipid exudates, or detection of these features
on the color image.
5. OCT: The interpretation of OCT scans at each visit
was made by the site clinician. A positive test was
defined as the presence of signs of clinically relevant
and active nAMD on constituent B scans of the
macular raster captured by spectral domain OCT.
Clinicians classified OCT as exhibiting nAMD if
there were regions of hyporeflectivity within the
neurosensory retina indicating accumulation of
intraretinal fluid between the neurosensory retina
and the retinal pigment epithelium representing
subretinal fluid or an increasing pigment epithelial
detachment. Shallow irregular elevation of the
retinal pigment epithelium without subretinal fluid
was not considered a trigger. Regions of hyper-
reflectivity in the subretinal space (subretinal
hyperreflective material) indicating the presence of
abnormal blood vessels, fibrin, and cellular elements
were a trigger.Reference Standards
The findings of the FFA at capture in the clinic were the
primary reference standard read by the site clinician who
was not masked to index test findings. The classification of
the FFA was based on traditional angiographic interpreta-
tion of the leakage patterns on FFA leading to the diagnosis
of the presence of nAMD.
We prespecified 2 additional reference standards
(Table S1, available at www.aaojournal.org). An enhanced
reference standard that was an independent assessment of
the FFA by an ophthalmic reading center was included
because it is known that disagreements can exist between
clinician detection of the onset of nAMD on an FFA and
that undertaken by trained graders.13 Graders were masked
to index test results and evaluated the FFA for features of
nAMD based on a prespecified grading protocol. A
pragmatic reference standard included clinician decision
on conversion to nAMD based on FFA and those who
could not be imaged with FFA at the time of onset of
nAMD because of health concerns or because the
participant declined. The FFA procedure and its
interpretation in determining the primary and enhanced
reference standards are described in Appendix S1
(available at www.aaojournal.org).Outcomes
Primary Outcome
The primary outcome was the sensitivity and specificity of
the index tests compared with the primary reference stan-
dard and only included participants whose diagnosis of
conversion to nAMD or not in the EDNA study eye was
based on the FFA interpretation by the site clinician.
Sivaprasad et al  Tests for Fellow Eyes of Unilateral Wet AMDSecondary Outcomes
Secondary outcomes included sensitivity and specificity of
the index tests compared with the enhanced reference
standard, diagnostic odds ratio (DOR), likelihood ratio, and
proportions of indeterminate tests. Other outcomes included
the sensitivity and specificity of combinations of tests.Sample Size
The sample size calculation was based on comparative
diagnostic accuracy to ensure the ability to detect differ-
ences in sensitivity and specificity between candidate tests
based on McNemar’s test.14 Under the primary analysis, a
positive candidate test result was defined as any positive
result during the monitoring period on the respective test.
At 2-sided 5% significance level and 90% power, a paired
difference of 15% (80% to 65%) in sensitivity required 491
participants (560 allowing for indeterminate/missing data
results, including participants lost to follow-up cumulatively
of up to 12%) given a cumulative incidence of 28% at 3
years.15 A smaller difference in specificity was also
identifiable (7%; 94% to 87% with power and significance
levels as before). The sample size was also sufficient to
detect differences in sensitivity and specificity of 20% or
more at the same power and significance levels even if the
sensitivities/specificities were substantially lower (e.g.,
60% to 40%) or the previous difference if the level of
missing data is higher (e.g., 20%). These calculations
assumed disagreement between tests was at least at the
level observed in a similar analysis of data on another eye
condition (74% of maximum possible; disagreement of
0.30 and 0.13 for the main sensitivity and specificity
calculations).16
Statistical Analyses
We conducted our analyses using Stata version 15 (Stata-
Corp LP) following a predefined statistical analysis plan.
We summarized the baseline characteristics of participants.
If no reference standard was available at any point after
baseline, the participant was excluded from all subsequent
analyses.
For each participant, we defined the end of the follow-up
as the date of the last FFA providing 1 of the following 2
criteria were met: (1) The final FFA showed no nAMD and
there was at least 1 prior index test result; (2) the final FFA
showed nAMD and an index test result was obtained within
the previous 3 months. If neither criterion was met, we used
the result of an FFA from a prior visit to define the end of
the monitoring period.
We then collapsed the test results obtained from baseline
until the end of the valid follow-up period, defined earlier, to
obtain a single positive or negative test result. We classified
any positive test over the valid follow-up period as an
overall positive result. To be a negative test result, all test
results over the valid follow-up period had to be negative.
Cross tabulations of index tests against the primary refer-
ence standard were performed.We had multiple reference standards, but our prespecified
primary reference standard was clinician determination of
conversion to nAMD based on the FFA. For all reference
standards, we calculated sensitivity and specificity with 95%
confidence intervals (CIs) using the Agresti-Coull method
and positive and negative likelihood ratios with 95% CIs
using the method proposed by Zhou et al.17 We also
computed likelihood ratios, which are an estimate of the
probability of accuracy of detection of disease by the
index test, considered by some to be the preferable means
of summarizing of diagnostic accuracy of a test. We
calculated the DORs and the proportion of indeterminate
tests with 95% CIs. We compared the monitoring
sensitivity and specificity of the tests using McNemar’s
statistical test (with 95% CIs produced using Newcombe’s
method).18 Additional analyses assessed the sensitivity and
specificity of the index tests under the following
conditions: varying the definition of the time period over
which a positive index test was considered (the last 6
months of participants’ follow-up or using only the last
available index test). When cases were included in the
analysis, we handled missing data in several ways. If ac-
cording to the protocol a reference standard should have
been performed but was not undertaken, the missing refer-
ence standard was presumed to indicate a negative result at
that visit. When FFAs were deemed to be indeterminate,
they were treated as missing, and sensitivity analyses were
performed to assess the impact of this assumption. Similar
analyses were conducted using the enhanced reference
standard.
By using the primary reference standard and all available
index test results over the full monitoring period, the effect
of combinations of OCT with each of the other index tests
was investigated. The positive result was defined in 2 ways:
(1) when either of the tests was positive and (2) when both
tests had to be positive. We also examined 2 additional
combinations of index tests after excluding OCT: (1) the
combination of the 4 index tests other than OCT and (2) the
combination of only those index tests that assessed function
(self-reported vision, Amsler test, and VA).Results
Participant Characteristics
Between June 2015 and March 2017, 949 potential partic-
ipants seen in 24 NHS eye clinics were approached, of
whom 578 consented to take part in the EDNA study.
Figure 1 shows the flow of participants from enrollment
until exit or development of nAMD in the EDNA study
eye. After excluding those who had been consented in
error or withdrew consent, 552 formed the final cohort,
and the baseline characteristics of this group are shown in
Table 1.
The average number of clinic visits for the entire cohort
was 15.6 (standard deviation [SD], 7.7) during follow-up
(range, 1e35). In participants who developed nAMD in
the study eye, the average number of clinic visits was 10.1
(SD, 6.7) and 19.0 (SD, 6.0) for those who did not develop1739
Figure 1. Flowchart of participants included in the main and enhanced reference standards. EDNA ¼ Early Detection of Neovascular Age-Related Macular
Degeneration; FFA ¼ fundus fluorescein angiography; nAMD ¼ neovascular age-related macular degeneration.
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over the 3-year period is shown in Table S2 (available at
www.aaojournal.org). The proportion of visits with index
tests completed were self-reported vision 90%, Amsler
88%, VA check 99%, fundus examination 91%, and OCT
93%. The average follow-up period in participants who
developed nAMD in the study eye was shorter at 14 months
(IQR, 7.7e23.0) compared with those who did not develop
nAMD, which was 35 months (IQR, 29.7e36.5). A positive
Amsler test was recorded in 92 participants (17%) at the
baseline visit, so this index test was not conducted during
follow-up in this subset. During the study, 145 participants
developed active nAMD in the EDNA study eye. In 120
participants (83.0%), a confirmatory FFA was available and
read by the site clinician. The crude conversion rate of
development of new nAMD (based on the 456 participants
who constituted the primary reference standard) in the
EDNA study eye was 26% (95% CI, 22e31) with a median
follow-up time of 33 months (range, 0.8e38.5 months) (Fig
S2, available at www.aaojournal.org).
Table S3 (available at www.aaojournal.org) shows the
interval in days between the date of the primary reference
standard and that of the relevant index test grouped by
conversion to nAMD in the study eye. In the majority of
participants who converted to nAMD, the positive index
test triggered the reference standard on the same day. In
participants who did not develop nAMD in their study eye
during follow-up, the interval between final set of index
tests and the final FFA ranged from an average of 8 days for
self-reported vision and 117 days for VA.1740Diagnostic Accuracy
The numbers of participants included in the primary,
enhanced, and pragmatic reference standards are shown in
Figure 1 and Table S4 (available at www.aaojournal.org).
Table 2 shows cross tabulations of index test results
versus the primary reference standard. In participants with
FFA-confirmed new-onset nAMD with data on subjective
vision loss in the EDNA study eye (n ¼ 118), self-reported
vision was “a bit worse” in 19, “worse” in 13, and “much
worse” in 5. The Amsler was positive in 33 (n ¼ 98).
Reduction in VA in the EDNA study eye from baseline to
onset of nAMD of 10 or more letters was recorded in 36
(n ¼ 120), whereas a decrease of 5 or more letters and 15 or
more letters was recorded in 77 and 22 participants,
respectively. Fundus examination/color imaging revealed
new nAMD in 64 (n ¼ 119). Features of onset of nAMD
were recorded as present on OCT in 110 of the 120
confirmed conversions.
When FFA was negative for new nAMD, 10 of 337 self-
reported “much worse” vision loss, 52 of 279 had a positive
Amsler test, and 113 of 335 had a 10-letter VA loss recorded
by that visit. Features of onset of nAMD were noted as
present on fundus clinical examination in 8 of the 335 in
whom FFA confirmed the absence of neovascularization.
Clinical signs of exudation were deemed as present in the
OCT scans of 41 of the 335 with a negative FFA (Table 2).
Sensitivity and specificity of the index tests were calcu-
lated on the basis of the primary reference standard of FFA
read by the site clinician and determined to have developed
Table 2. Cross Tabulations of Index Test Results versus Primary
Reference Standard (n ¼ 456)
Index test FFA DVE FFA -ve All
Self-reported vision same 81 280 361
Self-reported vision bit worse 19 30 49
Self-reported vision worse 13 18 31
Self-reported vision much worse* 5 8 13
All 118 336 454
Amsler þve 33 52 85
Amsler -ve 65 227 292
All 98 279 377
VA fall of 5 letters þve 77 231 308
VA fall of 5 letters -ve 43 104 147
VA fall of 10 letters þve*,y 36 113 149
VA fall of 10 letters -vey 84 222 306
VA fall of 15 letters þve 22 55 77
VA fall of 15 letters -ve 98 280 378
VA fall of 20 letters þve 13 6 77
VA fall of 20 letters -ve 107 329 378
All 120 335 455
Fundus clinical exam þve 64 8 72
Fundus clinical exam -ve 55 327 382
All 119 335 460
OCT þve 110 41 151
OCT -ve 10 294 394
All 120 335 455
FFA ¼ fundus fluorescein angiography; VA ¼ visual acuity.
þve refers to a positive test as defined in the prespecified statistical analysis
plan. For self-reported VA, a positive test result was much worse. A positive
Amsler is one for which distortion or blank spaces were reported where
previously there was none. Decrease in VA of 10 or more letters was
considered a positive test result. Fundus clinical examination was positive if
signs of new-onset nAMD was detected on slit-lamp biomicroscopy or a
color photograph. OCT was test positive if new-onset intraretinal or sub-
retinal fluid or subretinal hyperreflective material was detected. The -ve
indicates the numbers in which the index tests were classified as negative.
Missing data. A follow-up FFA was not acquired in 79 participants, of
whom 25 were clinically judged to have developed nAMD. The FFA was
inconclusive in 8 participants. Participants who did not have a follow-up
FFA or in whom the FFA was inconclusive were excluded from the pri-
mary reference standard. Amsler was not performed in 90 participants who
had a positive Amsler at baseline. At follow-up, Amsler and self-reported
VA were missing in 2 participants. Clinic VA was missing in 1 participant.
*An FFA was triggered by a positive test.
yThe prespecified primary analysis was based on a decrease of 10 letters from
baseline at any time point during the follow-up period.
Table 1. Participant Characteristics (n ¼ 552)
Characteristic n (% n/552)
Age, yrs, mean (SD), n 77.4 (7.7), 552
BMI - mean (SD), n 27.6 (5.3), 423
Male gender 236 (42.8)
Hypertension* 292 (52.9)
Cardiovascular disease* 118 (21.4)
Family history of AMD* 82 (14.9)
History of diabetes* 88 (15.9)
Other systemic disorders* 48 (8.7)
Nutritional supplements* 165 (29.9)
Current smoker* 70 (12.7)
Ex-smoker 264 (47.8)
Never smoked 217 (39.3)
Ocular characteristics in the EDNA study eye
Study eye is better-seeing eye 525 (95.1)
VA (ETDRS letters) in study eye (mean, SD) 79 (5.4)
Amsler test scotoma presenty 92 (16.7)
Scotoma absent 460 (83.3)
Lens statusy
Cataract present 285 (51.6)
Phakic cataract absent 148 (26.8)
Pseudophakic 117 (21.2)
BMI ¼ body mass index; EDNA ¼ Early Detection of Neovascular Age-
Related Macular Degeneration; VA ¼ visual acuity.
*Clinical history was not captured in 1 participant.
yAmsler test and lens status missing in 2 participants.
Sivaprasad et al  Tests for Fellow Eyes of Unilateral Wet AMDactive nAMD. Table 3 shows that the sensitivity of OCT
was markedly higher at 91.7% compared with those of all
other tests that ranged from 4.2% to 53.8%. Fundus
clinical examination had the highest specificity (97.9%),
followed by self-reported vision (97%) and OCT (87.8%).
Changing to the enhanced reference standard (Table 4)
resulted in a small reduction of sensitivity and specificity
of the OCT compared with the primary reference standard.
Specificities remained largely unchanged for all the index
tests between enhanced and primary reference standards.
Table S4 (available at www.aaojournal.org) shows the
cross tabulations of clinician determination of conversions
to nAMD versus the reading center. Figure 2A to D
summarizes the sensitivities and specificities of the index
tests against the primary and enhanced reference standards
and for the secondary analyses varying the definitions of
the time periods over which the index tests were
considered. Table S5 (available at www.aaojournal.org)
shows the sensitivity and specificity of the index tests
against clinical judgment of conversion to active nAMD
in the 145 participants. Pairwise comparisons of sensitivity
and specificity of the various index tests revealed
statistically significant differences (Table S6, available at
www.aaojournal.org).
The positive and negative likelihood ratios (and 95% CI)
are shown in Table S7 (available at www.aaojournal.org).
OCT had a high positive likelihood ratio and very low
negative likelihood ratio. Fundus clinical examination had
a high positive likelihood ratio, but the negative likelihood
ratio was fivefold greater than for OCT. Estimated DORs
varied greatly from 0.8 (VA) to 79.5 (OCT).Sensitivity and Specificity of Combinations of
Tests
On examining the combination of OCT and 1 other index
test when either test could be positive for an overall positive
result, sensitivity increased marginally for combinations,
achieving 96% for OCT and VA, and specificity decreased
except for OCT combined with fundus examination
(Table S8, available at www.aaojournal.org). When both
tests had to be positive (Table S9, available at
www.aaojournal.org), for the combination to be classified
as overall positive, sensitivity was reduced for all
combinations compared with that of OCT by itself but
was offset by improvements in specificity (although of
smaller magnitude). By combining all index tests except
OCT, the sensitivity of this combination was lower than1741
Table 3. Sensitivity and Specificity of Index Tests Against the Primary Reference Standard (Clinician Determination of Conversion to











Self-reported visiony 4.2 (1.6e9.8) 5/118 97.0 (94.6e98.5) 327/337
Amsler testz 33.7 (25.1e43.5) 33/98 81.4 (76.4e85.5) 227/279
VAx 30.0 (22.5e38.7) 36/120 66.3 (61.0e71.1) 222/335
Fundus clinical examinationk 53.8 (44.8e62.5) 64/119 97.6 (95.3e98.9) 327/335
OCT{ 91.7 (85.2e95.6) 110/120 87.8 (83.8e90.9) 294/335
CI ¼ confidence interval; FFA ¼ fundus fluorescein angiography; nAMD ¼ neovascular age-related macular degeneration.







Ophthalmology Volume 128, Number 12, December 2021that achieved with OCT alone. By excluding fundus clinical
examination, with the combinations consisting only of tests
that reflected function (self-reported vision, Amsler test, and
VA), sensitivity decreased by approximately 20%. For
combinations that excluded OCT or both OCT and fundus
clinical examination, specificities were similar and
remained lower than combinations that included OCT
(Table S10, available at www.aaojournal.org).Discussion
This diagnostic accuracy study of monitoring fellow eyes
of participants with unilateral nAMD at baseline compared
5 commonly performed index tests with the reference
standard of FFA. On the basis of the detection of conver-
sion to nAMD in the study eye by FFA, we have shown
conclusively that compared with the other index tests, OCT
has the best diagnostic accuracy (highest combination of
sensitivity and specificity) with clear statistical evidence of






Self-reported vision* 3.4 (1.1e8.7) 4/11
Amsler testy 31.6 (23.1e41.5) 30/95
VAz 27.7 (20.5e36.4) 33/11
Fundus clinical examinationx 50.0 (41.1e58.9) 59/11
OCTk 85.7 (78.2e91.0) 102/11
CI ¼ confidence interval; FFA ¼ fundus fluorescein angiography; nAMD ¼ ne






1742periods chosen for at least up to 3 years after the diagnosis
of nAMD in the first eye. We varied the reference standard
and index test definitions to mimic clinical and research
situations and considered combinations of index tests. We
found that all analyses pointed clearly to OCT as the most
accurate index test and suitable for use on its own.
Although self-reported vision and clinical examination
showed high specificity, these and the other index tests
apart from OCT performed poorly for sensitivity and are
therefore unsuitable for monitoring for the onset of nAMD.
In addition to the diagnostic accuracy of an index test, we
took into consideration the ease of performing a test and its
availability for monitoring in routine clinical practice in the
current UK NHS settings. We showed that the index tests
were conducted at a very high proportion of visits. Because
data were collected during usual care, the findings from this
pragmatic study are readily applicable in routine clinical
practice.
Data are limited on the accuracy of monitoring tests of
fellow eyes of patients with nAMD in 1 eye. In a cohort








7 97.1 (94.6e98.5) 331/341
81.0 (76.0e85.1) 230/284
9 66.2 (61.0e71.0) 225/340
8 95.6 (92.8e97.4) 325/340
9 83.5 (79.2e87.1) 284/340
ovascular age-related macular degeneration; VA ¼ visual acuity.
because of missing data; 119 study eyes developed nAMD, and 341 did not.
Figure 2. Sensitivity of index tests (A) using the primary reference standard (clinician determination based on FFA) and (B) using the enhanced reference
standard (reading center determination based on FFA). Test performance is shown in the 3 panels separated by dotted lines. The time periods are all visits,
last 6 months of follow-up, and final visit. Index test performance remained similar regardless of the time period, with sensitivities that are lowest for self-
reported vision moderate and similar for Amsler test and visual acuity (VA), good for fundus examination, and best for OCT. Specificity of index tests (C)
using the primary reference standard (clinician determination based on FFA) and (D) enhanced reference standard (reading center determination based on
FFA). The time periods are all visits, last 6 months of follow-up, and final visit. Index test performance. Specificities were clustered at the high end and the
performance of the index tests were not altered by changing the time period. EDNA[ Early Detection of Neovascular Age-Related Macular Degeneration;
FFA ¼ fundus fluorescein angiography; nAMD ¼ neovascular age-related macular degeneration.
Sivaprasad et al  Tests for Fellow Eyes of Unilateral Wet AMDmonitored the unaffected fellow eyes with OCT, supervised
Amsler test, preferential hyperacuity perimetry (PHP), and
best-corrected VA every 3 months for 2 years or until
development of nAMD for 2 years, which occurred in 17%.
The tests showed low to moderate sensitivity (0.5), but
this is unsurprising, because the time domain OCT used by
Do et al19 has poor vertical resolution. The PHP test is
performed on specialized equipment and requires patient
training and compliance, with a high proportion failing to
perform the test properly, which made it unsuitable for
routine use.20 The Home study, which was nested within
the Age-Related Eye Diseases Study 2, reported that the
ForeseeHome, a device based on PHP designed for use in
the community, had a sensitivity of 82% and specificity of
88% compared with a sensitivity of 70% and specificity of
95%, which was based on detection of new-onset nAMD on
color stereo photographs read by a group of retina special-
ists.21 The Home study compared the ForseeHome system
with self-monitoring of visual symptoms in the detection
of incident nAMD, and the mean VA loss at the time of
detection of new nAMD in the former was 4 letterscompared with 9 letters in the latter.21 Self-reported decline
in visual function and standard nonrefracted clinic-based
VA, clinical examination, and OCT were not included;
therefore, the data from the Home study are not directly
comparable to the findings from EDNA. A recent analysis of
the ForeseeHome device reported that its utility in the
detection of new-onset nAMD based on data collected from
routine clinical care fell considerably short of its previously
reported accuracy.21 Notably, a small proportion of the
sample were able to establish a baseline, and of those who
did, 92% of the alerts were false-positive. The foregoing
emphasizes the need for continuing evaluation of moni-
toring devices that can be used in the home setting before
their introduction into routine clinical practice for the
detection of the onset of nAMD. In this context, recent
developments in devices that are capable of monitoring of
patients with exudative maculopathies with OCT in the
community also require rigorous evaluation.
With respect to other studies that have compared OCT
with FFA, one that was undertaken in the clinical setting on
patients referred for nAMD reported a sensitivity and1743
Ophthalmology Volume 128, Number 12, December 2021specificity for OCT alone in detecting nAMD as 100% and
80.8%, respectively.10 However, 17% were false-positives.
Furthermore, this study differs from EDNA in its
cross-sectional design, retrospective analysis, and a lack of
any other commonly performed monitoring tests.10
An important finding of some concern in EDNA was the
poor diagnostic accuracy of self-reported visual function.
Less than one-fifth of the participants reported a change in
vision that was worse or much worse at detection of onset of
nAMD in the EDNA study eye. Additionally, approximately
10% of our patients had worsening of vision that was shown
not to be due to the onset of nAMD. Our study monitoring
committee included a number of patient experts who were
involved in the study design and interpretation of findings.
One reason suggested by one of our patient experts was that
any sudden deterioration in acuity that occurs at onset of
nAMD had been masked by a gradual decline in vision in
the interim, which in itself may have triggered adaptive
strategies. The finding that it is not possible to rely on self-
reported visual deterioration as a marker for the onset of
nAMD is particularly disturbing because the study eye was
required to have a VA of 68 or more ETDRS letters (Snellen
20/40 or better) at enrollment. This degree of function
represents driving-level VA, and it is notable that in more
than 95% of participants the study eye was the eye with
better acuity. Thus, the inability of our patient population to
recognize a change in function in the EDNA study eye
around the time of onset of nAMD is both surprising and
worrying because it is common clinical practice to ask pa-
tients to self-monitor for worsening of vision or the onset of
distortion.5 The other self-administered test, which involves
recording the appearance of a scotoma or a distortion on the
Amsler chart, also had poor sensitivity and specificity,
which is a recognized drawback of this tool.20
It was notable that a decrease in VA measured at clinic
visits also showed poor sensitivity. We considered a decrease
of 10 letters (2 ETDRS lines) as an event that would be
recognized by participants as a change in function of sufficient
severity that could be due to the onset of nAMD. However,
among the 120 participants who were confirmed with new-
onset nAMD in the study eye, less than half had a decrease
in VA of 10 or more letters, and conversely of the 335who did
not develop nAMD, around one-third had a decrease in VA of
 10 letters. Possible reasons, including VA loss secondary to
atrophy of the macular tissues22 and cataract,23 emphasize the
need for awareness of comorbidities that can result in
functional impairment in this age group. Furthermore, inter-
session repeatability of VA measurements can vary consid-
erably. The poor performance of VA is a major concern for
several reasons. First, because of the COVID crisis, there is
currently a strong emphasis on home monitoring for detection
of new-onset nAMD, which include web-based applications
of the Amsler test and visual function measurements. Our
study clearly confirms that reliance on psychophysical tech-
nologies that measure visual change or self-reported symp-
tomswill result in both a lower detection rate and higher false-
positive rate. Considering this risk-benefit ratio, it is important
to evaluate home-monitoring devices using visual function to
monitor AMD diagnosis or treatment response in pragmatic
trials conducted in real-world settings before introducing them1744into clinical practice.21,24 Second, to minimize patient
interaction, many clinics are currently choosing not to
perform a monitoring OCT in patients who attend for
follow-up treatment in their first eye. Our data show that
asking patients to report the appearance of new symptoms or
reliance on measures of acuity, even those obtained in the
clinic, can result in underdetection of the onset of nAMD in the
at-risk eye. In fact, our study results recommend further
research on remote monitoring using OCT rather than visual
function measures.25
Study Strengths and Limitations
Our study has multiple strengths. First, EDNA is the largest
prospectively designed multicenter monitoring study of pa-
tients with existing nAMD in 1 eye that compared multiple
pragmatic candidate tests in their ability to detect the onset of
nAMD in the contralateral eye, which was the designated
study eye. In addition to sensitivity and specificity, with the
standard measures of diagnostic accuracy, following our pre-
specified statistical analysis plan, we calculated likelihood
ratios and DORs providing further clarity on the performance
of the index tests. Likelihood ratios indicate the clinical im-
plications of using a test more clearly than sensitivity and
specificity. Tests may be better at ruling in disease (higher
positive likelihood ratio) or ruling out disease (lower negative
likelihood ratio). The DOR reflects a single combined quan-
tification of the diagnostic value of the test. OCT had the
highest positive likelihood ratio and lowest negative likeli-
hood ratio, thus indicating it performed better than any of the
other tests in terms of both ruling on the onset of nAMD and
ruling out absence of conversion to onset of nAMD. Second,
EDNA is representative of a wide population because patients
were recruited from 24 NHS Trusts across the United
Kingdom and the rate of progression to nAMD in the EDNA
study eye was comparable to previous longitudinal cohorts
with nAMD in the contralateral eye,6,15 emphasizing the
generalizability of our study results. Third, index tests were
captured at most routine clinic visits with only a small
proportion not carried out when a participant had attended a
visit. Fourth, through inclusion of FFA at month 18 and the
exit visit, we were confident that study eyes were free of
nAMD at these time points. This allowed us to obtain robust
estimates of sensitivity and specificity of the index tests
under the principal analysis. Fifth, because clinicians do not
agree in the interpretation of an FFA26 and disagreements
can also exist between clinician detection of the onset of
nAMD and trained graders working in a reading center,13
we included an enhanced reference standard. Although the
primary reference standard representing routine clinical
practice may be associated with high risk of bias, the
enhanced reference standard that was provided by masked
graders in an independent reading center confirms the
validity of our findings. We included persons with AMD as
advisors in our study steering group, who helped in the
conduct and interpretation of the study findings.
Our study has several limitations. First, we did not include
OCT angiography as one of the test technologies. This is a
recently introduced, novel, noninvasive method of imaging
the retinal and choroidal vasculature with potential to reveal
Sivaprasad et al  Tests for Fellow Eyes of Unilateral Wet AMDthe presence of neovascular complexes of nAMD.27Although
OCT angiography has become rapidly adopted within the
retina community in the developed world as a confirmatory
test for nAMD, it is not yet widely available in many
countries. Furthermore, reports on its accuracy compared
with FFA suggest that diagnosis may be confounded by
artifacts and other conditions.12,28,29 Second, in 12% of
participants who were diagnosed as having developed
nAMD during follow-up, FFA was lacking. In most cases,
this was due to patient preference not to have the invasive test
or clinical caution in persons who had developedmild allergic
reactions to previous injections of fluorescein dye. However,
sensitivity analyses based on the clinical diagnosis of con-
version to nAMD did not alter the findings (data shown in
supplementary materials, Table S4 and S5). Third, 25
participants (representing 17% of the 145 who were
classified as having developed active nAMD) did not have a
confirmatory FFA and were excluded from the calculations
of diagnostic accuracy in the main analysis. Nonetheless,
because the main analysis showed that the sensitivity of
OCT was extremely high at 92%, it is highly likely that if
the remaining 25 participants had been imaged with FFA, a
similar performance would have been observed. We note
the similarity in test performance between the primary and
pragmatic reference standards. Fourth, our study enrolled
persons who had a confirmed diagnosis of nAMD in 1 eye
already and therefore had a high probability that macular
pathology that developed subsequently in the fellow eye
was likely due to AMD. We determined the sample size and
selection criteria based on the most robust data for both rate
and highest risk of conversion to nAMD.30 Our study did
not include persons with bilateral intermediate AMD, who
are also at increased risk,30 but the reported rates of
conversion in such a group would have necessitated a large
sample, which was not possible within the allocated
resources. We recognize that other exudative maculopathies
that also occur in the older age groups can exhibit similarfeatures on OCT and may result in misclassification and a
higher false-positive rate. Nonetheless, our data offer strong
support for the use of OCT for the detection of nAMD at
earliest onset in the wider population. Fifth, in a small pro-
portion of participants who were classified as not having
converted to nAMD in the EDNA study eye, the FFA refer-
ence standardwas not carried out for repeatedly positive index
tests because of its invasive nature and concerns about patient
safety. This approach reflects clinical practice in the United
Kingdom, but because additional FFAs at 18 and 36months in
the study were undertaken, it is unlikely that any true con-
versions were missed. Last, as participants exited the study at
onset of nAMD in the study eye and were treated, we were
unable to assess whether tests with a false-negative result
might have become positive at a later stage. Despite these
limitations of our study, the diagnostic accuracy findings in
this monitoring context are striking and robust.
In conclusion, the findings of the EDNA study are of
relevance globally because the monitoring strategy outlined
in currently applicable guidelines, such as the American
Academy of Ophthalmology Preferred Practice Pattern,5
places high reliance on self-reporting of change in visual
function and Amsler test, which has been shown in EDNA
to have poor sensitivity and only moderate specificity.
Because the risk of progression to nAMD in the unaffected
fellow eyes of a patient with nAMD in 1 eye may be as high
as 50% within 5 years of diagnosis,6 the use of OCT as a
monitoring tool has considerable potential for cost
savings.9,31 Treatment for nAMD imposes a significant
burden for patients, their carers, and hospital facilities, and
a diagnostic test of such high sensitivity and specificity
has important implications in terms of acceptability to
patients and can help streamline care pathways and reduce
the impact on hospital intravitreal injection services. In
terms of diagnostic accuracy, based on our findings
presented, a revised strategy to monitor such patients with
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